

8 Literaturverzeichnis

1. Krebs in Deutschland. 4. überarbeitete, aktualisierte Ausgabe. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland. Saarbrücken, 2004.
2. Atzpodien J, Kuchler T, Wandert T, Reitz M. Rapid deterioration in quality of life during interleukin-2- and alpha-interferon-based home therapy of renal cell carcinoma is associated with a good outcome. *Br J Cancer* 2003;89:50-4.
3. Brinkmann OA, Roigas J, Hertle L. [Systemic immunotherapie of metastatic renal cell carcinoma and long-term outcome]. *Urologe A* 2002;41:231-8.
4. Thoenes W, Störkel S, Rumpelt HJ. Histopathology of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. *Pathol Res Pract* 1986;181:125-43.
5. Klöppel G, Knöfel WT, Baisch H, Otto U. Prognosis of renal cell carcinoma related to nuclear grade, DNA content and Robson stage. *Eur Urol* 1986;12: 426-31.
6. Schmitz-Dräger BJ, Ebert T, Vögeli T. Retroperitoneale Weichteiltumoren. In „Uro-Onkologie“, Herausgeber H. Rübben. Springer Verlag, Berlin, Heidelberg, 1997, pp 543-564.
7. Sobin LH, Wittelund CH. TNM-Classification of malignant tumors. UICC, 5th edition, 1997, pp 180-182.
8. Golimbu M, Joshi P, Sperber A, Tessler A, Al-Askari S, Morales P. Renal cell carcinoma: Survival and prognostic factors. *Urology* 1986;27:291-301.
9. Skinner DG, Vermillion CD, Colvin RB. The surgical management of renal cell carcinoma. *J Urol* 1972;107:705-10.
10. Porzolt F, Wölpl CP, Rist CE, Büchele G, Gaus W. Vergleich von drei Instrumenten, die gesundheitsbezogene Lebensqualität/Qualität von Wohlbefinden messen. In „Derzeitiger Stand und Aspekte der Lebensqualitätsforschung in der urologischen Onkologie“, Herausgeber C.W. Biermann. W. Zuckschwerdt Verlag München, 1996, pp 105-119.

11. Wille A, Roigas J, Deger S. Palliative Behandlungen und Lebensqualität beim metastasierten Nierenzellkarzinom. In „Nierenzellkarzinom“, Herausgeber Schnorr D, Loening SA. Blackwell Wissenschafts-Verlag Berlin, Wien, 1998, pp 144-145.
12. Wagner H, Oberneder R, Busch M, Weiss M, Schmeller N, Perides P. Nierenkarzinom. In „Tumorzentrum München, Empfehlungen zur Diagnostik, Therapie und Nachsorge, Urogenitale Tumoren“, Herausgeber Tumorzentrum München, 1997, pp 74-93.
13. Tosaka A, Ohya K, Yamada K, et al. Incidence and properties of renal masses and asymptomatic renal cell carcinoma detected by abdominal ultrasonography. J Urol 1990;144:1097-9.
14. Ebert T, Ackermann R, Bander NH. Biological markers in renal cell carcinoma. Urologe A 1990;29:65-70.
15. May M, Seehafer M, Helke C, Übereück T, Gunia S, Hoschke B. Superior vena cava syndrome with bilateral jugular and subclavian vein thrombosis. Paraneoplastic manifestation of renal cell carcinoma. Urologe A 2003;42:1374-7.
16. Pollack HM, Banner MP, Arger PH, Peters J, Mulhern CB Jr, Coleman BG. The accuracy of gray-scale renal ultrasonography in differentiating cystic neoplasms from benign cysts. Radiology 1982;143:741-5.
17. Mittelstaedt CA. In „Abdominal ultrasound“. Churchill Livingstone, New York, 1987, p 356.
18. Berg-Schlosser V. Radiologische Diagnostik maligner Nierentumoren. In „Deutsches Ärzteblatt“, Herausgeber Deutscher Ärzteverlag GmbH Köln, 1988, pp 390-394.
19. Tammela TL, Leinonen AS, Kontturi MJ. Comparison of excretory urography, angiography, ultrasound and computed tomography for T category staging of renal cell carcinoma. Scand J Urol Nephrol 1991;25:283-6.
20. Marberger M. Organerhaltende Nierentumorexzision. Akt Urol 1988;19:58-66.
21. Thompson IM, Peek M. Improvement in survival of patients with renal cell carcinoma – the role of the serendipitously detected tumor. J Urol 1988;140:487-90.
22. Rogalla P, Taupitz M, Hamm B. Modern imaging modalities in renal disease: CT and MRI. Urologe A 2003;42:187-96.

23. Goldfarb DA, Novick AC, Lorig R, et al. Magnetic resonance imaging for assessment of vena caval tumor thrombi: A comparative study with venocavography and computerized tomography scanning. *J Urol* 1990;144:1100-3.
24. Talley RW, Moorhead EL 2nd, Tucker WG, San Diego EL, Brennan MJ. Treatment of metastatic hypernephroma. *JAMA* 1969;207:322-8.
25. Montie JE, Stewart BH, Straffon RA, Banowsky LH, Hewitt CB, Montague DK. The role of adjunctive nephrectomy in patients with renal cell carcinoma. *J Urol* 1977;117:272-5.
26. Pritchett TR, Lieskovsky G, Skinner DG. Clinical manifestations and treatment of renal parenchymal tumors. In "Diagnosis and therapy of genitourinary tumors", Herausgeber Skinner DJ, Lieskovsky G. WB Saunders, Philadelphia, 1988.
27. Golimbu M, Al-Askari S, Tessler A, Morales P. Aggressive treatment of metastatic renal cancer. *J Urol* 1986;136:805-7.
28. de Kernion JB, Ramming KP, Smith RB. The natural history of metastatic renal cell carcinoma: a computer analysis. *J Urol* 1978;120:148-52.
29. Kradjian RM, Bennington JL. Renal carcinoma recurrent 31 years after nephrectomy. *Arch Surg* 1965;90:192-5.
30. May M, Marusch F, Kaufmann O, et al. Solitary renal cell carcinoma metastasis to the thyroid gland – a paradigm of metastasectomy. *Chirurg* 2003;74:768-74.
31. Thomas J, Stott M, Royle GT. Spontaneous regression of subcutaneous and pulmonary metastases from renal carcinoma. *Br J Urol* 1989;63:102-3.
32. Bennett RT, Lerner SE, Taub HC, Dutcher JP, Fleischmann J. Cytoreductive surgery for stage IV renal cell carcinoma. *J Urol* 1995;154:41-2.
33. Taneja SS, Pierce WC, Figlin RA, Belldegrun A. Management of disseminated kidney cancer. *Urol Clin North Am* 1994;21:625-37.
34. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R; European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon-alfa alone in metastatic renal-cell carcinoma: a randomised trial. *Lancet* 2001;358:948-9.

35. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. *N Engl J Med* 2001;345:1655-9.
36. Pantuck AJ, Belldegrun AS, Figlin RA. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. *N Engl J Med* 2001;345:1711-2.
37. Fisher RI, Coltman CA Jr., Doroshow JH, et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. *Ann Intern Med* 1988;108:518-23.
38. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. *Urol Clin North Am* 1993;20:303-21.
39. Walther NM, Alexander RB, Weiss GH, et al. Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. *Urology* 1993;42:250-7.
40. von Eschenbach AC, Avallone A, Price J, et al. The biology of renal cancer: the influence of nephrectomy. *Eur Urol* 1990;18 Suppl 2:40-1.
41. Fleischmann JD, Kim B. Interleukin-2-immunotherapy followed by resection of residual renal cell carcinoma. *J Urol* 1991;145:938-41.
42. Spencer WF, Linehan WM, Walther MM, et al. Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study. *J Urol* 1992;147:24-30.
43. Naito S, Kimiya K, Sakamoto N, et al. Prognostic factors and value of adjunctive nephrectomy in patients with stage IV renal cell carcinoma. *Urology* 1991;37:95-9.
44. O'Connell JR, McCaffrey JA, Motzer RJ, Gomella LG, Friedland DM. What is the role of nephrectomy in patients with metastatic renal cell carcinoma? *Semin Oncol* 1996;23:17.
45. Türk I. Rolle der Nephrektomie beim metastasierten Nierenzellkarzinom (Literaturübersicht). In „Nierenzellkarzinom“, Herausgeber D. Schnorr, S.A. Loening. Blackwell Wissenschafts-Verlag, Berlin, Wien, 1998, pp 111-117.
46. Piltz S, Meimarakis G, Wichmann M, Oberneder R, Jauch KW, Fürst H. Surgical treatment of pulmonary metastases from renal cancer. *Urologe A* 2003;42:1230-7.
47. Tschada R, Henkel T, Rassweiler J, Alken P. Palliative Metastasen Chirurgie versus konservative Therapie beim progredienten Nierenzellkarzinom. *Urologe A* 1994;33 Suppl 1:73.

48. Romaniuk P. Stellenwert der Embolisation von Nierentumoren. In „Nierenzellkarzinom“, Herausgeber D. Schnorr, S.A. Loening. Blackwell Wissenschafts-Verlag Berlin, Wien, 1998, pp 68-74.
49. Aulitzky WE, Kaufmann M. Immunotherapy for advanced renal cell carcinoma. *Urologe A* 2004;43:85-92.
50. Mickisch G, Bier H, Bergler W, Bak M, Tschada R, Alken P. P-170 glycoprotein, glutathione and associated enzymes in relation to chemoresistance of primary human renal cell carcinomas. *Urol Int* 1990;45:170-6.
51. Hrushesky WJ, Murphy GP. Current status of the therapy of advanced renal carcinoma. *J Surg Oncol* 1977;9:277-88.
52. Atzpodien J, Kirchner H, Illiger HJ, et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. *Br J Cancer* 2001;85:1130-6.
53. Pizzocaro G, Piva L, Salvioni R, Di Fronzo G, Ronchi E, Miodini P. Adjuvant medroxyprogesterone acetate and steroid hormone receptors in Category M0 renal cell carcinoma. An interim report of a prospective randomized study. *J Urol* 1986;135:18-21.
54. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases: final results of the Radiation Therapy Oncology Group. *Cancer* 1982;50:893-9.
55. Garmatis CJ, Chu FC. The effectiveness of radiation therapy in the treatment of bone metastases from breast cancer. *Radiology* 1978;126:235-7.
56. Siebels M, Oberneder R, Buchner A, et al. Ambulatory radiosurgery in cerebral metastatic renal cell carcinoma. 5-year outcome in 58 patients. *Urologe A* 2002;41:482-8.
57. Brinkmann OA, Bruns F, Prott FJ, Hertle L. Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC). *Anticancer Res* 1999;19:1583-7.
58. Strohmeyer T. Genterapeutische Ansätze beim Nierenzellkarzinom – Ist die Zukunft bereits Gegenwart? In „Nierenzellkarzinom“ Herausgeber D. Schnorr, S.A. Loening. Blackwell Wissenschafts-Verlag Berlin, Wien, 1998, pp 194-201.
59. Heinzer H, Huland E, Huland H. Treatment of metastatic renal cell carcinoma. Value of immunotherapy compared with surgery of metastases. *Urologe A* 2000;39:356-61.

60. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. *N Engl J Med* 1985;313:1485-92.
61. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. *N Engl J Med* 1987;316:889-97.
62. Roigas J, Deger S, Schröder J, Schnorr D. Chemoimmuntherapie des metastasierten Nierenzellkarzinoms an der Klinik für Urologie der Charite – Erfahrungen und Ergebnisse. In „Nierenzellkarzinom“, Herausgeber D. Schnorr, S.A. Loening. Blackwell Wissenschafts-Verlag Berlin, Wien, 1998, pp 138-143.
63. Vogl W, Osterhage HR, Kaiser L. Metastasiertes Nierenzellkarzinom. Ungewöhnlicher Verlauf nach Operation und autologer Tumorzellvakzinierung. *Urologe B* 1999;39:419-422.
64. Steiner T, Weirich T, Schubert J. Stellenwerte der aktiv-spezifischen Immunisierung (ASI) in der Therapie des Nierenzellkarzinoms. *Urologe B* 2000;40:358-361.
65. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumor vaccine and risk of tumor progression in patients with renal-cell carcinoma after radical nephrectomy: phase III randomized controlled trial. *Lancet* 2004;363:594-9.
66. Atzpodien J, Buer J, Sel S, Janssen J, Oevermann K. Chemoimmunotherapy in the systemic treatment of advanced renal carcinoma. *Urologe A* 1999;38:474-8.
67. Roigas J, Deger S, Taymoorian K, et al. Effects of 13-cis-retinoic acid on chemoimmunotherapy of metastatic renal cell carcinoma- -results of a retrospective analysis. *Cancer Biother Radiopharm* 2003;18:157-63.
68. Atzpodien J, Royston P, Wandert T, Reitz M, DGCIN -- German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group. Metastatic renal carcinoma comprehensive prognostic system. *B J Cancer* 2003;88:348-53.
69. Atzpodien J, Kirchner H, Poliwoda H. Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma. *Med Klin (Munich)* 1996;91 Suppl 3:38-43.
70. Hofmockel G, Langer W, Theiss M, Gruss A, Frohmüller HG. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil. *J Urol* 1996;156:18-21.

71. Huland E, Heinzer H, Huland H. Behandlung des pulmonal metastasierten Nierenzellkarzinoms mit inhalativem Interleukin-2. Erfahrungen der letzten 6 Jahre. In „Nierenzellkarzinom“, Herausgeber D. Schnorr, S.A. Loening. Blackwell Wissenschafts-Verlag Berlin, Wien, 1998 pp 151-159.
72. Lopez-Hänninen E, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 1996;155:19-25.
73. Oberneder R, Kriegmair M, Staehler M, Hofstetter A. Immunotherapy of metastatic renal cell carcinoma. Is clinical use justified in view of outcome, side effects and costs? Urologe A 1997;36:130-7.
74. Volkmer BG, Gschwend JE. Value of metastases surgery in metastatic renal cell carcinoma. Urologe A 2002;41:225-30.
75. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17:2859-67.
76. Coppin C, Porzsolt F, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2000;(3):CD001425.
77. Jacqmin D, Bergerat JP, Dufour P, et al. Medical treatment of metastatic cancer of the kidney with a combination of vinblastine and recombinant interferon alpha IIa. Result of a phase I-II trial. J Urol (Paris) 1987;93:463-6.
78. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96.
79. Fossa SD, Martinelli G, Otto U, et al. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. Ann Oncol 1992;3:301-5.
80. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338:1272-8.
81. Atzpodien J, Kirchner H, Hänninen EL, Deckert M, Fenner M, Poliwoda H. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 1993;29A Suppl 5:S6-8.
82. Kirchner H, et al. Risks and long-term outcome in metastatic renal cell carcinoma patients receiving sc interleukin-2, sc interferon-alfa2a and iv 5-fluorouracil. Abstract presented at ASCO 1998, Abstract 1195.

83. Atzpodien J, Kirchner H, Jonas U, et al. Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Interleukin-2- and interferon Alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). *J Clin Oncol* 2004;22:1188-94.
84. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. *J Clin Oncol* 1999;17:2530-40.
85. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. *Cancer Res* 1988;48:7310-3.
86. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. *J Clin Oncol* 2002;20:4559-66.